| Literature DB >> 35569825 |
Matthew J L Hare1,2, Yuejen Zhao3, Steven Guthridge4, Paul Burgess3,5, Elizabeth L M Barr4,6, Elna Ellis7, Deborah Butler8, Amy Rosser9, Henrik Falhammar10,11, Louise J Maple-Brown4,2.
Abstract
OBJECTIVES: To assess the prevalence and incidence of diabetes among Aboriginal peoples in remote communities of the Northern Territory (NT), Australia.Entities:
Keywords: EPIDEMIOLOGY; General diabetes; PUBLIC HEALTH
Mesh:
Year: 2022 PMID: 35569825 PMCID: PMC9125760 DOI: 10.1136/bmjopen-2021-059716
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1Map of the Top End (TE) and Central Australia (CA) regions of the Northern Territory, Australia, showing the 51 remote clinics (triangles) and 6 hospitals (crosses) contributing data to this study. There are two hospitals in the location at the top left (North West) of the Top End. Distances and locations are approximate.
Figure 2Trend in crude diabetes prevalence among Aboriginal people (all ages) in remote Northern Territory communities over 7 years. Error bars are 95% CIs. Note the vast majority of prevalent diagnoses were classified as type 2 diabetes (98.6% type 2, 0.17% type 1 and 0.07% other diabetes in 2018/2019).
Figure 3Age and sex-specific diabetes prevalence in 2018/2019 among Aboriginal people in remote Northern Territory communities. Error bars are 95% CIs.
Characteristics of Aboriginal people with prevalent diabetes in 2018/2019 in the NT, with comparison by region
| Total NT (n=3477) | Central Australia (n=1382) | Top End (n=2095) | P value (CA vs TE) | |
| Age, years | 49 (39–58) | 48 (37–58) | 49 (40–58) | 0.003 |
| Female | 2115 (61) | 834 (60) | 1281 (61) | 0.637 |
| Diabetes type | 0.269 | |||
| 3429 (98.6) | 1368 (98.9) | 2061 (98.4) | ||
| 34 (1.0) | 9 (0.7) | 25 (1.2) | ||
| 14 (0.4) | 5 (0.5) | 9 (0.4) | ||
| Treatment | ||||
| 1627 (47) | 542 (39) | 1085 (52) | <0.001 | |
| 1181 (34) | 508 (37) | 673 (32) | 0.005 | |
| 610 (18) | 307 (22) | 303 (15) | <0.001 | |
| 59 (1.7) | 25 (1.8) | 34 (1.6) | 0.678 | |
| Mean HbA1c* | ||||
| 7.9 (±0.04) | 8.4 (±0.07) | 7.7 (±0.05) | <0.001 | |
| 63 (±0.4) | 68 (±0.8) | 61 (±0.5) | ||
| Median HbA1c* | ||||
| 7.2 (6.1–9.4) | 7.8 (6.3–10.1) | 7.0 (6.0–8.9) | <0.001 | |
| 55 (43–79) | 62 (45–87) | 53 (42–74) | ||
| HbA1c category* | <0.001 | |||
| 1216 (35) | 375 (27) | 641 (40) | ||
| 415 (12) | 159 (12) | 256 (12) | ||
| 540 (16) | 228 (17) | 312 (15) | ||
| 567 (16) | 281 (20) | 286 (14) | ||
| 739 (21) | 339 (25) | 400 (19) |
Data are n (%), median (IQR) or mean (±SE).
*The single most recent HbA1c result for each individual within the 2018/2019 year was included. Individuals with no HbA1c in that 12-month period were excluded from calculation of means/medians and reported in the ‘no result’ category.
CA, Central Australia; GLT, glucose lowering therapy; HbA1c, haemoglobin A1c; NT, Northern Territory; TE, Top End.
Figure 4Age-specific diabetes incidence rates between 2016/2017 and 2018/2019 among Aboriginal people in remote Northern Territory communities. Error bars are 95% CIs. Out of 483 incident diabetes diagnoses, 481 (99.6%) were recorded as type 2 diabetes.